GYNOSTEMMA PENTAPHYLLUM-CONTAINING HEALTH CARE PHARMACEUTICAL COMPOSITION FOR PREVENTING HYPERLIPIDEMIA, HYPERTENSION, HYPERGLYCEMIA AND GOUT

Abstract

A gynostemma pentaphyllum-containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia and gout is prepared by mixing raw materials of gynostemma pentaphyllum, folium eucommiae, folium mori, semen plantaginis, herba lophatheri, pueraria mirifica powder, pelargonium graveolens and sanguisorba minor, and the raw materials are in percentage by mass: 40-70% of gynostemma pentaphyllum, 5-20% of folium eucommiae, 5-20% of folium mori, 5-10% of semen plantaginis, 2-10% of herba lophatheri, 2-10% of pueraria mirifica powder, 2-8% of pelargonium graveolens and 2-8% of sanguisorba minor. The gynostemma pentaphyllum is prepared by mixing diploid gynostemma pentaphyllum leaves and tetraploid gynostemma pentaphyllum leaves according to a ratio. The pharmaceutical composition is mainly aimed at people who suffer from hyperlipidemia, hypertension, hyperglycemia and hyperuricemia, and used for preventing and treating the four hypers

Claims

1. A gynostemma pentaphyllum-containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia and gout, prepared by mixing raw materials of gynostemma pentaphyllum, folium eucommiae, folium mori, semen plantaginis, herba lophatheri, pueraria mirifica powder, pelargonium graveolens and sanguisorba minor, wherein the raw materials are in percentage by mass: 40-70% of gynostemma pentaphyllum, 5-20% of folium eucommiae, 5-20% of folium mori, 5-10% of semen plantaginis, 2-10% of herba lophatheri, 2-10%0/of pueraria mirifica powder, 2-8% of pelargonium graveolens and 2-8% of sanguisorba minor.

2. The gynostemma pentaphyllum-containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia and gout according to claim 1, wherein the pharmaceutical composition is prepared by mixing the following raw materials in percentage by mass: 50-70% of gynostemma pentaphyllum, 6-12% of folium eucommiae, 6-12% of folium mori, 6-12% of semen plantaginis, 6-8% of herba lophatheri, 6-8% of pueraria mirifica powder, 2-5% of pelargonium graveolens and 2-5% of sanguisorba minor.

3. The gynostemma pentaphyllum-containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia and gout according to claim 2, wherein the pharmaceutical composition is prepared by mixing the following raw materials in percentage by mass: 60% of gynostemma pentaphyllum, 10% of folium eucommiae, 10% of folium mori, 4% of semen plantaginis, 4% of herba lophatheri, 4% of pueraria mirifica powder, 4% of pelargonium graveolens and 4% of sanguisorba minor.

4. The gynostemma pentaphyllum-containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia and gout according to claim 1, wherein the gynostemma pentaphyllum is prepared by mixing diploid gynostemma pentaphyllum leaves and tetraploid gynostemma pentaphyllum leaves.

5. The gynostemma pentaphyllum-containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia and gout according to claim 4, wherein a mass ratio of the diploid gynostemma pentaphyllum leaves to the tetraploid gynostemma pentaphyllum leaves is 2:5 to 5:2.

6. The gynostemma pentaphyllum-containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia and gout according to claim 5, wherein the mass ratio of the diploid gynostemma pentaphyllum leaves to the tetraploid gynostemma pentaphyllum leaves is 1:1.

7. The gynostemma pentaphyllum-containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia and gout according to claim 1, wherein the pharmaceutical composition is prepared into tablets, pills, dissolved medicines, granules and powder.

8. An application of the gynostemma pentaphyllum-containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia and gout according to claim 1, wherein the pharmaceutical composition is used for preventing and treating hyperlipidemia, hypertension, hyperglycemia and hyperuricemia.

Description

DETAILED DESCRIPTION OF THE EMBODIMENTS

[0028] The present invention is further described below in combination with embodiments. Percentages in the embodiments are all weight percentages, but the present disclosure is not limited to this.

Embodiment 1

[0029] 30% of diploid gynostemma pentaphyllum, 30% of tetraploid gynostemma pentaphyllum, 10% of folium eucommiae, 10% of folium mori, 4% of semen plantaginis, 4% of herba lophatheri, 4% of pueraria mirifica powder, 4% of pelargonium graveolens and 4% of sanguisorba minor.

Embodiment 2

[0030] 20% of diploid gynostemma pentaphyllum, 50% of tetraploid gynostemma pentaphyllum, 5% of folium eucommiae, 5% of folium mori, 10% of semen plantaginis, 2% of herba lophatheri, 2% of pueraria mirifica powder, 2% of pelargonium graveolens and 4% of sanguisorba minor.

Embodiment 3

[0031] 50% of diploid gynostemma pentaphyllum, 20% of tetraploid gynostemma pentaphyllum, 6% of folium eucommiae, 5% of folium mori, 6% of semen plantaginis, 6% of herba lophatheri, 3% of pueraria mirifica powder, 2% of pelargonium graveolens and 2% of sanguisorba minor.

Embodiment 4

[0032] 25% of diploid gynostemma pentaphyllum, 25% of tetraploid gynostemma pentaphyllum, 12% of folium eucommiae, 12% of folium mori, 5% of semen plantaginis, 6% of herba lophatheri, 5% of pueraria mirifica powder, 5% of pelargonium graveolens and 5% of sanguisorba minor.

Embodiment 5

[0033] 20% of diploid gynostemma pentaphyllum, 20% of tetraploid gynostemma pentaphyllum, 15% of folium eucommiae, 15% of folium mori, 10% of semen plantaginis, 8% of herba lophatheri, 5% of pueraria mirifica powder, 5% of pelargonium graveolens and 2% of sanguisorba minor.

Embodiment 6

[0034] 15% of diploid gynostemma pentaphyllum, 30% of tetraploid gynostemma pentaphyllum, 18% of folium eucommiae, 15% of folium mori, 6% of semen plantaginis, 6% of herba lophatheri, 3% of pueraria mirifica powder, 2% of pelargonium graveolens and 5% of sanguisorba minor.

Embodiment 7

[0035] 30% of diploid gynostemma pentaphyllum, 15% of tetraploid gynostemma pentaphyllum, 15% of folium eucommiae, 15% of folium mori, 8% of semen plantaginis, 8% of herba lophatheri, 5% of pueraria mirifica powder, 2% of pelargonium graveolens and 2% of sanguisorba minor.

Embodiment 8

[0036] 20% of diploid gynostemma pentaphyllum, 20% of tetraploid gynostemma pentaphyllum, 15% of folium eucommiae, 10% of folium mori, 9% of semen plantaginis, 5% of herba lophatheri, 5% of pueraria mirifica powder, 8% of pelargonium graveolens and 8% of sanguisorba minor.

Embodiment 9 Clinical Embodiments of a Compound Preparation in the Present Disclosure for Treating Gouty Arthritis

[0037] Gout belongs to the category of arthralgia, and is also called joint-running wind, severe and migratory arthralgia, white tiger joint running and the like. Modern medicine thinks that, the gout is a group of heterogeneous chronic metabolic diseases caused by purine metabolism disorders, and may be divided into an asymptomatic hyperuricemia phase, an acute attack phase of gouty arthritis, an intercritical phase and a chronic phase.

[0038] In recent years, along with booming development of traditional Chinese medicine, on the basis of inheriting traditional therapy, traditional Chinese medicine treatment researches of the gout are combined with modern medical experiments, and there are many treatment methods such as internal treatment, external treatment, internal and external combined treatment and the like.

[0039] 9.1 Data and Methods

[0040] 60 patients suffering from warm-heat pathogen stagnancy type acute gouty arthritis after clinical diagnosis are selected as research objects. The patients include 36 male patients and 24 female patients, are aged at 51-72, and have an average age of 621.2.

[0041] With reference to Guiding principles for Clinical Research of New Drugs of Traditional Chinese Medicine and Criteria of Diagnosis and Therapeutic Effect of Internal Diseases and Syndromes in Traditional Chinese Medicine in State Administration of Traditional Chinese Medicine, clinical manifestations of warm-heat pathogen stagnancy type patients suffering from gout are as follows:

[0042] Primary symptoms: involved joint burning, red and swollen, and pain from acute onset, and inconvenient flexing and stretching of joints.

[0043] Secondary symptoms: fever, tiredness, expectoration or bitter taste, loose stool discomfort or inhibited defecation, and short and yellow urinating.

[0044] Tongue vein: reddened tongue, yellow and greasy tongue, soggy pulse or slippery pulse or slip.

[0045] The patients should eat low-calorie, low-protein and low-purine foods, strictly withdraw alcohol and particularly beer, drink fructose-containing beverages and yogurt as less as possible, and keep daily water intake at least 2500 mL; the patients should get more rest, keep joint immobilization as much as possible, elevate the injured limb, avoid a heavy load and wear comfortable shoes to avoid the injury of joints; the patients should avoid overfatigue, cold or damp, mental stress and the like, and take medicines that influence uric acid excretion with caution. The compound preparation in the present invention is taken for three times per day at a dosage of 3 g each time. A course of treatment lasts 10 days, and the patients should be continuously treated within 2 courses of treatment.

[0046] 9.2 Observation Indicators

[0047] Blood urea nitrogen (BUN), serum creatinine (Cr), alanine aminotransferase (ALT), aspartate amino transferase (AST) and other hepatorenal functions before and after treatment.

[0048] 9.3 Evaluation of Therapeutic Effects

[0049] Evaluation of clinical therapeutic effects includes determination of therapeutic effects of syndromes of traditional Chinese medicine and determination of clinical comprehensive therapeutic effects. A criterion of the determination of therapeutic effects of syndromes of traditional Chinese medicine is set with reference to Criteria of Diagnosis and Therapeutic Effect of Syndromes in Traditional Chinese Medicine in State Administration of Traditional Chinese Medicine; and a criterion of determination of clinical comprehensive therapeutic effects is drawn up with reference to Guiding principles for Clinical Research of New Drugs of Traditional Chinese Medicine.

[0050] Clinical control: clinical symptoms and signs disappear or basically disappear, and a syndrome integral is decreased.

[0051] Excellent: the clinical symptoms and signs are obviously improved, and the syndrome integral is decreased.

[0052] Effective: the clinical symptoms and signs are improved, and the syndrome integral is decreased.

[0053] Ineffective: the clinical symptoms and signs are not obviously improved, or even worsened, and a decrease of the syndrome integral is insufficient.

[0054] 9.4 Therapeutic Results

TABLE-US-00001 TABLE 1 Present attack course of patients n 12 hours 1 day 3 days 3 days 40 4 25 8 3

TABLE-US-00002 TABLE 2 Comparison of inflammatory marks of patients before and after treatment (X S) Item Before treatment (n = 40) After treatment (n = 40) WBC (*109/L) 9.94 1.23 4.93 1.20 CRP (mg/L) 22.36 7.92 7.70 0.26 ESR (mm/H) 38.06 0.24 19.24 6.52

[0055] 9.5 Adverse Effects and Treatment:

[0056] (1) Influences on hepatorenal functions: after the present research and treatment solution is applied, a treatment group and a control group do not have any obvious abnormal change in detection of the hepatorenal functions such as BUN, Cr, ALT, AST and the like.

[0057] (2) Influences on digestive tract functions: after the present research and treatment solution is applied, some cases in the treatment group have an increase of defection frequency and relatively loose stool, but these symptoms are tolerable.

Embodiment 10

[0058] Products in embodiments 1-8 of the present invention are detected according to a national selenium-rich food standard GB28050-2011. Detection results show that selenium content is 0.20-5.00 mg/kg and meets the selenium-rich food standard. When detected by an improved new technology based on High Performance Liquid Chromatography (HPLC), the products contain 108.4-188.2 mg/g of saponins, 23.5-37.5 mg/g of polyphenols and 22.5-36.5 mg/g of general flavones. Although the present disclosure is described with reference to specific embodiments above, those of ordinary skill in the art should understand that, the above embodiments are only used for illustrating the present invention, rather than limiting the present invention. Changes and variations made to the above embodiments within the essential spirit of the present invention should be included in the protection scope of appended claims.